Sinovac Biotech (NASDAQ:SVA) focuses on the research, development, and commercialization of vaccines to combat infectious diseases. This biotech firm, traded on NASDAQ under the ticker SVA, is known for its advances in vaccine innovation, particularly in the creation of vaccines for diseases such as hepatitis, influenza, and COVID-19. Sinovac’s operations extend globally, with a commitment to improving public health through effective immunization solutions. Their efforts in vaccine development are augmented by ongoing partnerships and collaborations with international health organizations. The company's primary objective is to enhance accessibility to high-quality vaccines, especially in underrepresented regions, ultimately aiming to safeguard global populations against infectious outbreaks.